神经递质:一种新兴的瘤免疫检查点抑制剂治疗耐药性的目标
Jiyuan Yang1, Yu Wu1, Xinhui Lv1
1Dept. of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.
Molecular cancer
|August 12, 2025
概括
神经递质在癌症中显著影响免疫检查点抑制剂 (ICI) 的耐药性. 针对神经免疫轴提供了新的策略来提高ICI治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
背景情况:
- 免疫检查点抑制剂 (ICI),如抗PD-1/PD-L1和抗CTLA-4,增强抗瘤免疫力,但面临显著的耐药性.
- 瘤微环境因素和瘤细胞内在变化有助于ICI耐药性,限制了许多患者的持久疗效.
- 神经免疫轴,涉及神经递质和神经纤维,越来越多地被认为在免疫逃避和癌症进展中的作用.
研究的目的:
- 审查神经递质通过哪些机制影响瘤微环境,并有助于抵抗ICI的机制.
- 探索针对神经免疫轴的潜力,特别是神经递质及其受体,作为克服ICI耐药性的治疗策略.
- 为增强癌症免疫疗法的新方法提供见解.
主要方法:
- 对调查神经递质在癌症免疫力中的作用的研究进行文献综述.
- 分析神经递质 (多巴胺,北上腺素,血清素) 对瘤微环境中的免疫检查点表达和免疫细胞功能的影响.
- 探索针对神经递质通路的治疗策略,以提高ICI的疗效.
主要成果:
- 神经递质可以调节免疫细胞功能和免疫检查点表达,促进免疫逃脱并促进ICI耐药性.
- 瘤微环境中的失调的神经递质信号传递可能会损害抗瘤免疫反应.
- 准神经递质通路为克服对当前免疫疗法的耐药性提供了一个有希望的途径.
结论:
- 神经递质在抵抗免疫检查点抑制剂的过程中起着至关重要的作用.
- 通过针对神经递质的治疗来调节神经免疫轴,有可能改善癌症治疗结果.
- 对癌症神经免疫相互作用的进一步研究对于开发下一代免疫疗法至关重要.
更多相关视频
相关概念视频
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Mitogens and the Cell Cycle
6.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.7K


